Zobrazeno 1 - 10 of 10 pro vyhledávání: '"Adil al Hinai"'
1
Akademický článek
FLT3‐ITD mutations in acute myeloid leukaemia – molecular characteristics, distribution and numerical variation
Autor: Caroline Engen, Monica Hellesøy, Tim Grob, Adil Al Hinai, Atle Brendehaug, Line Wergeland, Siv Lise Bedringaas, Randi Hovland, Peter J. M. Valk, Bjørn T. Gjertsen
Publikováno v: Molecular Oncology, Vol 15, Iss 9, Pp 2300-2317 (2021)
Recurrent somatic internal tandem duplications (ITD) in the FMS‐like tyrosine kinase 3 (FLT3) gene characterise approximately one third of patients with acute myeloid leukaemia (AML), and FLT3‐ITD mutation status guides risk‐adapted treatment s
Externí odkaz: https://doaj.org/article/5c847808f7ca4069b952cc2692905f06
Zobrazit plný text záznamu
3
FLT3-ITD mutations in acute myeloid leukaemia – molecular characteristics, distribution and numerical variation
Autor: Line Wergeland, Siv Lise Bedringaas, Peter J. M. Valk, Adil Al Hinai, Atle Brendehaug, Monica Hellesøy, Caroline Engen, Tim Grob, Bjørn Tore Gjertsen, Randi Hovland
Publikováno v: Molecular Oncology, 15(9), 2300-2317. John Wiley & Sons Ltd.
Molecular Oncology
Molecular Oncology, Vol 15, Iss 9, Pp 2300-2317 (2021)
Recurrent somatic internal tandem duplications (ITD) in the FMS‐like tyrosine kinase 3 (FLT3) gene characterise approximately one third of patients with acute myeloid leukaemia (AML), and FLT3‐ITD mutation status guides risk‐adapted treatment s
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::537b99528ae4696620686c3be73f6d88
https://doi.org/10.1002/1878-0261.12961
Zobrazit plný text záznamu
4
Molecular Minimal Residual Disease Detection in Acute Myeloid Leukemia
Autor: Adil Al Hinai, Diana Hanekamp, Peter J. M. Valk, Christian M. Vonk
Publikováno v: Cancers, Vol 13, Iss 5431, p 5431 (2021)
Vonk, C M, Al Hinai, A S A, Hanekamp, D & Valk, P J M 2021, ' Molecular minimal residual disease detection in acute myeloid leukemia ', Cancers, vol. 13, no. 21, 5431 . https://doi.org/10.3390/cancers13215431
Cancers
Simple Summary Although the majority of patients with acute myeloid leukemia (AML) reach a morphologic complete remission after high-dose chemotherapy, the majority of them face a relapse within a few years. Detection of residual cells, persisting in
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8edcdfd1f1b384b4d4b52d84fd1b070
https://www.mdpi.com/2072-6694/13/21/5431
Zobrazit plný text záznamu
6
Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations
Autor: Mathijs A. Sanders, Sandra Kaiser, Wei Wang, Sarolta Bojtine Kovacs, Lars Bullinger, Bruno Cassinat, Annelieke Zeilemaker, Christoph Koellerer, Peter J. M. Valk, Jonas S. Jutzi, Titiksha Basu, Adil Al Hinai, Jenny Ostendorp, Brigitte Schlegelberger, Heike L. Pahl, Emmanuel Raffoux, Doris Steinemann, Maximilian Pellmann, Konrad Aumann
Publikováno v: Blood, 133(16), 1766-1777. American Society of Hematology
In acute myeloid leukemia (AML), acquired genetic aberrations carry prognostic implications and guide therapeutic decisions. Clinical algorithms have been improved by the incorporation of novel aberrations. Here, we report the presence and functional
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0460b0c0e4f0250bf829b6853f991b84
https://doi.org/10.1182/blood-2018-09-875047
Zobrazit plný text záznamu
7
Phosphoproteomic Characterization of Primary AML Samples and Relevance for Response Toward FLT3-inhibitors
Autor: Sonja Zweegman, Alexander A. Henneman, Connie R. Jimenez, Adil Al Hinai, Zinia J. Kwidama, Sander R. Piersma, David G. J. Cucchi, Bo J. van Kuijk, Jaco C. Knol, Jeroen Janssen, Thang V. Pham, Carolien van Alphen, Jacqueline Cloos
Publikováno v: HemaSphere. Wolters Kluwer Health
HemaSphere
HemaSphere, Vol 5, Iss 7, p e606 (2021)
HemaSphere, 6(7):e606. Wolters Kluwer Health
Cucchi, D G J, van Alphen, C, Zweegman, S, van Kuijk, B, Kwidama, Z J, Al Hinai, A, Henneman, A A, Knol, J C, Piersma, S R, Pham, T V, Jimenez, C R, Cloos, J & Janssen, J J W M 2021, ' Phosphoproteomic characterization of primary AML samples and relevance for response toward FLT3-inhibitors ', HemaSphere . https://doi.org/10.1097/HS9.0000000000000606
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf360b48998fe0847a28f815d75388a5
https://doi.org/10.1097/hs9.0000000000000606
Zobrazit plný text záznamu
8
Molecular Minimal Residual Disease in Acute Myeloid Leukemia
Autor: Patrycja L Gradowska, Tim Grob, Carlos Graux, Diana Hanekamp, Violaine Havelange, Adil Al Hinai, François G. Kavelaars, Mojca Jongen-Lavrencic, Marinus van Marwijk Kooy, Annelieke Zeilemaker, Bart J. Biemond, Bob Löwenberg, Mathijs A. Sanders, Markus G. Manz, Jakob Passweg, Rosa Meijer, Gerrit Jan Schuurhuis, Jacqueline Cloos, Gert J. Ossenkoppele, Peter J. M. Valk, Claudia A.J. Erpelinck-Verschueren, Thomas Pabst
Publikováno v: Jongen-Lavrencic, Mojca; Grob, Tim; Hanekamp, Diana; Kavelaars, François G; Al Hinai, Adil; Zeilemaker, Annelieke; Erpelinck-Verschueren, Claudia A J; Gradowska, Patrycja L; Meijer, Rosa; Cloos, Jacqueline; Biemond, Bart J; Graux, Carlos; van Marwijk Kooy, Marinus; Manz, Markus G; Pabst Müller, Thomas Niklaus; Passweg, Jakob R; Havelange, Violaine; Ossenkoppele, Gert J; Sanders, Mathijs A; Schuurhuis, Gerrit J; ... (2018). Molecular Minimal Residual Disease in Acute Myeloid Leukemia. New England journal of medicine NEJM, 378(13), pp. 1189-1199. Massachusetts Medical Society MMS 10.1056/NEJMoa1716863
New England Journal of Medicine, 378(13), 1189-1199. Massachussetts Medical Society
New England journal of medicine, 378(13), 1189-1199. Massachussetts Medical Society
Jongen-Lavrencic, M, Grob, T, Hanekamp, D, Kavelaars, F G, Al Hinai, A, Zeilemaker, A, Erpelinck-Verschueren, C A J, Gradowska, P L, Meijer, R, Cloos, J, Biemond, B J, Graux, C, van Marwijk Kooy, M, Manz, M G, Pabst, T, Passweg, J R, Havelange, V, Ossenkoppele, G J, Sanders, M A, Schuurhuis, G J, Löwenberg, B & Valk, P J M 2018, ' Molecular Minimal Residual Disease in Acute Myeloid Leukemia ', New England Journal of Medicine, vol. 378, no. 13, pp. 1189-1199 . https://doi.org/10.1056/NEJMoa1716863
The New England journal of medicine, Vol. 378, no. 13, p. 1189-1199 (2018)
BACKGROUND: Patients with acute myeloid leukemia (AML) often reach complete remission, but relapse rates remain high. Next-generation sequencing enables the detection of molecular minimal residual disease in virtually every patient, but its clinical
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2115adb936d578bc0d5a90c366f4ee25
Zobrazit plný text záznamu
9
Review: Aberrant EVI1 expression in acute myeloid leukaemia
Autor: Peter J. M. Valk, Adil Al Hinai
Publikováno v: British Journal of Haematology, 172(6), 870-878. Wiley-Blackwell Publishing Ltd
Deregulated expression of the ecotropic virus integration site 1 (EVI1) gene is the molecular hallmark of therapy-resistant myeloid malignancies bearing chromosomal inv(3)(q21q26·2) or t(3;3)(q21;q26·2) [hereafter referred to as inv(3)/t(3;3)] abno
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfe246dc5c0c712c58019ce86c0b7cf1
https://pubmed.ncbi.nlm.nih.gov/26729571
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje